Cabometyx

(Cabozantinib)

ApprovedSmall molecule

Cabozantinib is used to treat certain types of cancer, including kidney cancer, liver cancer, and thyroid cancer. It works by blocking proteins that help cancer cells grow and spread.[2] Cabometyx is currently approved and in use across 70 indications[4].[1]

Cabometyx is one of 744 small molecule programs targeting Liver Cancer. It is currently in Approved.

Indications

247

Total Trials

Active Trials

743

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Liver CancerTerminated

OsteosarcomaActive, not recruiting

Prostate CancerTerminated

Thyroid CancerActive, not recruiting

Metastatic Renal Cell CarcinomaRecruiting

Locally AdvancedTerminated

TrialRecruiting

Refractory Solid TumorsActive, not recruiting

Bladder Small Cell Neuroendocrine CarcinomaActive, not recruiting

High Grade Neuroendocrine NeoplasmsActive, not recruiting

Liver CancerPhase 2

Terminated

OsteosarcomaPhase 2

Active, not recruiting

Prostate CancerPhase 3

Terminated

Thyroid CancerApproved

Active, not recruiting

Metastatic Renal Cell CarcinomaPhase 2

Recruiting

Locally AdvancedPhase 2

Terminated

TrialPhase 2

Recruiting

Refractory Solid TumorsPhase 1

Active, not recruiting

Bladder Small Cell Neuroendocrine CarcinomaPhase 1

Active, not recruiting

High Grade Neuroendocrine NeoplasmsPhase 2

Active, not recruiting

Showing 10 of 70 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Approved

9 2

HLX43

Shanghai Henlius Biotech

Phase 3

3 3

Sigvotatug Vedotin

Pfizer

Phase 3

1 4

Remeron

OOrganon and Co

Preclinical

1 5

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Bladder Small Cell Neuroendocrine Carcinoma

NCT02496208

Q4 2026

Phase 3Active, not recruiting

Mcrpc

NCT04446117

Phase 2Active, not recruiting

Head and Neck Squamous Cell Cancer

NCT03468218

Phase 1Active, not recruiting

Renal Cell Carcinoma

NCT02293980

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT06535737

Phase 2Recruiting

Temozolomide

NCT04893785

Clinical

Trials by Indication[1]

Renal Cell Carcinoma22 trials

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03635892·60 enrolled

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT03634540·118 enrolled

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Unknown status·IIstituto Oncologico Veneto IRCCS··NCT04416646·100 enrolled

Show 19 more trials

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

Terminated· Roche logo

Roche·Phase 3·NCT04338269·522 enrolled

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Terminated·NNektar Therapeutics·Phase 3·NCT03729245·623 enrolled

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Active, not recruiting·EExelixis·Phase 3·NCT03937219·855 enrolled

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT02293980·110 enrolled

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Completed·EExelixis·Phase 3·NCT01865747·658 enrolled

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Terminated·AAravive, Inc.·Phase 1/2·NCT04300140·72 enrolled

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05931393·18 enrolled

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Completed·CCalithera Biosciences, Inc·Phase 2·NCT03428217·444 enrolled

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Completed·UUniversity of Colorado, Denver·Phase 1/2·NCT03149822·45 enrolled

Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases

Completed·CCentre Leon Berard·Phase 2·NCT03967522·26 enrolled

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06132945·2 enrolled

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Completed· Ipsen logo

Ipsen··NCT04353765·247 enrolled

Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma

Completed· Takeda logo

Takeda··NCT04804813·388 enrolled

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT03339219·35 enrolled

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03354884·23 enrolled

Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica··NCT06548867·80 enrolled

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

Terminated·GGenenta Science·Phase 1/2·NCT06716853·10 enrolled

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 4·NCT06934057·50 enrolled

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Completed·UUniversity of Utah·Phase 1·NCT03200587·12 enrolled

Hepatocellular Carcinoma16 trials

Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04511455·22 enrolled

A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab

Not yet recruiting·—·Phase 2·NCT06535737·40 enrolled

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03299946·15 enrolled

Show 13 more trials

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Completed·EExelixis·Phase 3·NCT01908426·707 enrolled

Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

Unknown status·IIstituto Clinico Humanitas·Phase 2·NCT04435977·46 enrolled

Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)

Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 2·NCT04316182·24 enrolled

Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)

Completed·HHospices Civils de Lyon·Phase 4·NCT03963206·110 enrolled

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Completed· Takeda logo

Takeda··NCT05100082·263 enrolled

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT04497038·3 enrolled

Cabozantinib in Hepatocellular Carcinoma

Active, not recruiting·SStephen Chan Lam·Phase 2·NCT04588051·20 enrolled

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

Active, not recruiting·EExelixis·Phase 3·NCT03755791·837 enrolled

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Recruiting·IIterion Therapeutics·Phase 1/2·NCT05797805·178 enrolled

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Withdrawn·OOHSU Knight Cancer Institute·Phase 2·NCT05327738

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

Completed·UUniversity of Leipzig·Phase 2·NCT04767906·16 enrolled

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT03586973·34 enrolled

A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function

Unknown status·JJohannes Gutenberg University Mainz·Phase 2·NCT04454762·20 enrolled

Prostate Cancer12 trials

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Completed·EExelixis·Phase 3·NCT01605227·1,028 enrolled

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Completed·WWashington University School of Medicine·Phase 1·NCT04477512·18 enrolled

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Terminated·UUniversity of Washington·Phase 2·NCT01703065·9 enrolled

Show 9 more trials

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Terminated·EExelixis·Phase 3·NCT01522443·119 enrolled

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01683994·49 enrolled

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Completed·MMassachusetts General Hospital·Phase 1·NCT01347788·34 enrolled

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Completed·UUniversity of Chicago·Phase 2·NCT01599793·19 enrolled

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Completed·WWeill Medical College of Cornell University·Phase 2·NCT04631744·4 enrolled

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

Terminated·—·Phase 2·NCT03964337·3 enrolled

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01428219·25 enrolled

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Completed·—·Phase 2·NCT01834651·17 enrolled

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Recruiting·UUniversity of Utah·Phase 2·NCT05168618·33 enrolled

Thyroid Cancer10 trials

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03630120·6 enrolled

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04211337·291 enrolled

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Active, not recruiting·EExelixis·Phase 4·NCT01896479·247 enrolled

Show 7 more trials

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Active, not recruiting·EExelixis·Phase 3·NCT03690388·187 enrolled

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Approved for marketing·EExelixis··NCT01683110

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01811212·25 enrolled

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Active, not recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT05660954·41 enrolled

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Withdrawn· Roche logo

Roche·Phase 3·NCT04760288

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Not yet recruiting·FFujian Medical University·Phase 4·NCT07010393·335 enrolled

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting·WWest China Hospital·Phase 2·NCT06482086·75 enrolled

Non-Small Cell Lung Cancer8 trials

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Unknown status·FFondazione Ricerca Traslazionale·Phase 2·NCT03911193·25 enrolled

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04151563

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT04471428·366 enrolled

Show 5 more trials

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Terminated·LLiza Villaruz, MD·Phase 2·NCT02132598·5 enrolled

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Terminated·—·Phase 1·NCT04173338·9 enrolled

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05613413·36 enrolled

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01866410·37 enrolled

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03468985·3 enrolled

100 more indications

Kidney Cancer7 trials

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Active, not recruiting·EEmory University·Phase 2·NCT04022343·22 enrolled

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04540705·30 enrolled

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Not yet recruiting·SSWOG Cancer Research Network·Phase 3·NCT07383441·718 enrolled

Show 4 more trials

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02761057·152 enrolled

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

Recruiting·MMark Stein·Phase 2·NCT04322955·48 enrolled

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Active, not recruiting·—·Phase 1·NCT05122546·31 enrolled

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835158·157 enrolled

Soft Tissue Sarcoma4 trials

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04551430·105 enrolled

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Active, not recruiting·—·Phase 2·NCT04200443·72 enrolled

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01755195·55 enrolled

Show 1 more trial

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Active, not recruiting·NNational Cancer Institute LAO·Phase 2·NCT05836571·66 enrolled

Trial4 trials

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients

Not yet recruiting·—·Phase 2·NCT05241561·24 enrolled

Show 1 more trial

A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT04427787·69 enrolled

Liver Cancer3 trials

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04204850·20 enrolled

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01658878·657 enrolled

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Terminated·UUniversity of Washington·Phase 2·NCT04442581·2 enrolled

Metastatic Colorectal Cancer2 trials

caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 2·NCT06171854·33 enrolled

Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer

Completed·JJohn Strickler, M.D.·Phase 1·NCT02008383·29 enrolled

Osteosarcoma2 trials

Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

Active, not recruiting· Ipsen logo

Ipsen·Phase 2·NCT06341712·10 enrolled

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05019703·40 enrolled

Refractory Solid Tumors2 trials

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05038839·44 enrolled

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Recruiting·PPeter Zage·Phase 1·NCT03611595·18 enrolled

Locally Advanced2 trials

Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Terminated·JJohannes Gutenberg University Mainz·Phase 2·NCT04066595·7 enrolled

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Recruiting·EEmory University·Phase 2·NCT06006013·21 enrolled

Head and Neck Squamous Cell Cancer2 trials

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Active, not recruiting·EEmory University·Phase 2·NCT03468218·36 enrolled

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03667482·20 enrolled

Breast Cancer2 trials

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Completed·—·Phase 2·NCT02260531·36 enrolled

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT01441947·68 enrolled

Multiple Myeloma2 trials

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Terminated·UUniversity of Nebraska·Phase 1/2·NCT03201250·11 enrolled

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Completed·MMassachusetts General Hospital·Phase 1·NCT01582295·4 enrolled

mCRPC2 trials

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Active, not recruiting·EExelixis·Phase 3·NCT04446117·575 enrolled

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

Completed·AAlfredo Berruti·Phase 2·NCT05265988·32 enrolled

Advanced Cancer2 trials

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Completed·EExelixis·Phase 1·NCT01553656·85 enrolled

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04514484·8 enrolled

Carcinoid Tumor2 trials

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Completed·—·Phase 2·NCT01466036·61 enrolled

Cabozantinib and Nivolumab for Carcinoid Tumors

Completed·—·Phase 2·NCT04197310·19 enrolled

Pancreatic Cancer2 trials

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT01663272·12 enrolled

Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer

Active, not recruiting·UUniversity of Arizona·Phase 2·NCT04820179·32 enrolled

Adrenocortical Carcinoma2 trials

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03370718·18 enrolled

Cabozantinib in Advanced Adrenocortical Carcinoma

Unknown status·WWuerzburg University Hospital·Phase 2·NCT03612232·37 enrolled

Melanoma2 trials

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Active, not recruiting·GGeorgetown University·Phase 2·NCT04091750·14 enrolled

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01835184·5 enrolled

Metastatic Prostate Cancer2 trials

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·N/A·NCT01812668·20 enrolled

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01630590·62 enrolled

Metastatic Urothelial Cancer2 trials

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Recruiting·EEmory University·Phase 1·NCT04878029·32 enrolled

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05092958·654 enrolled

Metastatic Melanoma2 trials

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835145·47 enrolled

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Terminated·JJohn Rieth·Phase 1/2·NCT03957551·28 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Recruiting·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT05048901·49 enrolled

Advanced Solid Tumors1 trial

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Recruiting·KKura Oncology, Inc.·Phase 1·NCT06026410·300 enrolled

Bladder Cancer1 trial

Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer

Active, not recruiting·DDeepak Kilari·Phase 2·NCT04289779·46 enrolled

Meningioma1 trial

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Recruiting·BBaptist Health South Florida·Phase 2·NCT05425004·24 enrolled

Colorectal Cancer1 trial

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT04963283·48 enrolled

Chemotherapy1 trial

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Terminated·EExelixis·Phase 2·NCT01995058·54 enrolled

Advanced Solid Malignancies1 trial

Cabozantinib in Advanced Solid Malignancies

Completed·MMassachusetts General Hospital·Phase 2·NCT01588821·37 enrolled

Carcinosarcoma1 trial

Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

Withdrawn·UUniversity of Alabama at Birmingham·Phase 2·NCT04149275

Renal Carcinoma1 trial

Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT04134390·25 enrolled

Pembrolizumab1 trial

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Completed·JJoseph Kim·Phase 2·NCT05052723·21 enrolled

Merkel Cell Carcinoma1 trial

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Terminated·—·Phase 2·NCT02036476·8 enrolled

Acute Myeloid Leukemia1 trial

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·MMassachusetts General Hospital·Phase 1·NCT01961765·18 enrolled

Cholangiocarcinoma1 trial

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01954745·19 enrolled

Refractory1 trial

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

Active, not recruiting·JJennifer King·Phase 2·NCT04876456·50 enrolled

Cytoreductive Nephrectomy1 trial

Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Terminated·FFundacion Oncosur·Phase 2·NCT06377722·18 enrolled

Immunotherapy1 trial

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

Completed·AAustralian and New Zealand Urogenital and Prostate Cancer Trials Group·Phase 2·NCT03685448·35 enrolled

Advanced Urothelial Cancer1 trial

Cabozantinib for Advanced Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01688999·69 enrolled

Relapse1 trial

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Terminated·EExelixis·Phase 2·NCT01068782·19 enrolled

Metastatic NSCLC1 trial

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Not yet recruiting·JJun Zhang, MD, PhD·Phase 2·NCT05859217·40 enrolled

Differentiated Thyroid Carcinoma1 trial

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Unknown status·TThomas Jefferson University·Phase 2·NCT02041260·43 enrolled

Advanced1 trial

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

Active, not recruiting·KKarsten Gavenis·Phase 2·NCT04524208·45 enrolled

Advanced Malignancies1 trial

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Completed·EExelixis·Phase 2·NCT00940225·730 enrolled

Central Nervous System Tumor1 trial

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Terminated·IIndiana University·Phase 2·NCT02885324·4 enrolled

Adult Subject1 trial

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

Completed·EExelixis·Phase 1·NCT01493869·26 enrolled

Neoplasms1 trial

Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT04400474·93 enrolled

Pancreatic Adenocarcinoma1 trial

Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Terminated·PPatrick Joseph Loehrer Sr.·Phase 2·NCT03213626·7 enrolled

Phase II1 trial

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC

Unknown status·UUniversity of Bologna·Phase 2·NCT04131543·25 enrolled

Function1 trial

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04522908·40 enrolled

Relapsed or Refractory1 trial

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01866293·11 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed·NNational Taiwan University Hospital·Phase 2·NCT05007613·24 enrolled

Temozolomide1 trial

A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

Recruiting·NNational Cancer Institute, Naples·Phase 2·NCT04893785·35 enrolled

Renal Cancer1 trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed· Novartis logo

Novartis·Phase 1·NCT03798626·167 enrolled

Triple Negative1 trial

Cabozantinib for Metastatic Triple Negative BrCa

Completed·—·Phase 2·NCT01738438·35 enrolled

Neuroendocrine Tumors1 trial

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT05249114·6 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting·EExelixis·Phase 1·NCT03170960·914 enrolled

Advanced Stage1 trial

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Recruiting·HHumanity & Health Medical Group Limited·Phase 2·NCT03899428·30 enrolled

Durvalumab1 trial

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03824691·122 enrolled

Treatment1 trial

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Completed· Ipsen logo

Ipsen··NCT04637204·1,540 enrolled

Squamous Cell Carcinoma1 trial

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03943602·37 enrolled

Clinical Trial1 trial

CARE1 Pragmatic Clinical Trial

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT06364631·1,250 enrolled

mCRC1 trial

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT04868773·12 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Precision Therapy in Refractory Tumor

Unknown status·BBaodong Qin·Phase 2·NCT03239015·300 enrolled

Endocrine Cancer1 trial

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Completed·MM.D. Anderson Cancer Center·N/A·NCT02592356·23 enrolled

Pediatric Solid Tumors1 trial

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05135975·86 enrolled

Salivary Gland Cancer1 trial

Cabozantinib in Advanced Salivary Gland Cancer Patients

Terminated·RRadboud University Medical Center·Phase 2·NCT03729297·25 enrolled

Combination Therapy1 trial

Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

Not yet recruiting·NNational Health Research Institutes, Taiwan·Phase 2·NCT07151326·60 enrolled

Plexiform Neurofibroma1 trial

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02101736·45 enrolled

Endometrial Cancer1 trial

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01935934·102 enrolled

Primary Peritoneal Cavity Cancer1 trial

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01716715·111 enrolled

Recurrent or Refractory Solid Tumors1 trial

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01709435·41 enrolled

Primary Peritoneal Cancer1 trial

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02315430·13 enrolled

Radiation Therapy1 trial

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Terminated·UUniversity of Washington·Phase 1/2·NCT04220229·6 enrolled

Cervical Cancer1 trial

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Terminated·UUniversity of South Alabama·Phase 2·NCT04230954·5 enrolled

Paraganglioma1 trial

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02302833·21 enrolled

Immunodeficiency1 trial

Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01822522·36 enrolled

Impaired Renal Function1 trial

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Completed·EExelixis·Phase 1·NCT01761773·32 enrolled

Triple-Negative Breast Cancer1 trial

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Completed·—·Phase 2·NCT03316586·18 enrolled

GIST1 trial

Ph II CABOGIST in GIST

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02216578·51 enrolled

Urothelial Carcinoma1 trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma

Completed·UUniversity of Utah·Phase 2·NCT03534804·37 enrolled

Esophageal Cancer1 trial

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Recruiting·AAnwaar Saeed·Phase 1/2·NCT03539822·117 enrolled

Genomic Alterations1 trial

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02795156·100 enrolled

Tyrosine Kinase Inhibitor1 trial

A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05039736

Cutaneous Melanoma1 trial

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Terminated·PProvidence Health & Services·Phase 2·NCT05200143·4 enrolled

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05048212·20 enrolled

Adrenal Cortical Carcinoma1 trial

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06900595·48 enrolled

Metastatic Renal Cell Carcinoma1 trial

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Recruiting·NNRG Oncology·Phase 2·NCT05327686·240 enrolled

Metastatic Digestive System Neuroendocrine Tumor G11 trial

NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05773274·100 enrolled

Clinical Stage III Cutaneous Melanoma AJCC v81 trial

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05136196·150 enrolled

Bladder Adenocarcinoma1 trial

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03866382·314 enrolled

High Grade Neuroendocrine Neoplasms1 trial

Cabozantinib in High Grade Neuroendocrine Neoplasms

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04412629·35 enrolled

Autoimmune1 trial

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816345·300 enrolled

Advanced Clear Cell Renal Cell Carcinoma1 trial

A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05012371·90 enrolled

Advanced Renal Cell Carcinoma (RCC)1 trial

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07293351·474 enrolled

Metastatic Nasopharyngeal Carcinoma1 trial

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Suspended·NNational Cancer Institute (NCI)·Phase 2·NCT05904080·50 enrolled

Bladder Small Cell Neuroendocrine Carcinoma1 trial

A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02496208·152 enrolled

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma1 trial

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04310007·117 enrolled

Recurrent Lung Non-Small Cell Carcinoma1 trial

A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT01708954·125 enrolled

Unspecified3 trials

XL-184+Abiraterone in Post-Chemo CRPC

Completed·—·Phase 1·NCT01574937·27 enrolled

Spanish Real-World Evidence Cabozantinib

Completed·SSpanish Oncology Genito-Urinary Group··NCT04510688·275 enrolled

Cabozantinib With Topotecan-Cyclophosphamide

Completed·—·Phase 1·NCT04661852·12 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 25, 2016

CABOMETYX

NDA NDA208692

Dec 19, 2017

CABOMETYX

NDA NDA208692

Jan 14, 2019

CABOMETYX

NDA NDA208692

Jan 31, 2020

CABOMETYX

NDA NDA208692

Jul 16, 2020

CABOMETYX

NDA NDA208692

Nov 5, 2020

CABOMETYX

NDA NDA208692

Jan 22, 2021

CABOMETYX

NDA NDA208692

Sep 17, 2021

CABOMETYX

NDA NDA208692

Jul 14, 2022

CABOMETYX

NDA NDA208692

Feb 13, 2023

CABOMETYX

NDA NDA208692

Sep 20, 2023

CABOMETYX

NDA NDA208692

Mar 26, 2025

CABOMETYX

NDA NDA208692

Sep 10, 2025

CABOMETYX

NDA NDA208692

Oct 9, 2025

CABOMETYX

NDA NDA208692

Sources

References

[1]
ClinicalTrials.gov — 247 trial records for Cabozantinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Cabometyx drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cabozantinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cabozantinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA208692). U.S. Food & Drug Administration.
[6]
PubMed — 1 publication indexed for Cabozantinib. U.S. National Library of Medicine.
[7]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Multi-Kinase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Key Publications[6]

Cabozantinib Plus Nivolumab in Advanced Renal Cell Carcinoma: CheckMate 9ER

N Engl J MedMar 3, 2022DOI: 10.1056/NEJMoa2205821